Published Journal Articles on Fibrolamellar
The table below contains a complete listing of important peer-reviewed scientific publications on fibrolamellar carcinoma. Specific articles, authors and topics can be found by using the search box.
| Publication date | Article title | Journal name | First author of the article | Other authors of the article | Corresponding author of the article | Link to article summary |
|---|---|---|---|---|---|---|
| 28-Feb-14 | Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma | Science | Joshua N. Honeyman, Elana P. Simon, Nicolas Robine | Rachel Chiaroni-Clarke, David G. Darcy, Irene Isabel P. Lim, Caroline E. Gleason, Jennifer Murphy, Brad R. Rosenberg, Lydia Teegan, Constantin N. Takacs, Sergio Botero, Rachel Belote, Soren Germer, Anne-Katrin Emde, Vladimir Vacic, Umesh Bhanot, Michael P. LaQuaglia | Sanford M. Simon | Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma |
| 1-Dec-14 | The genomic landscape of fibrolamellar hepatocellular carcinoma: whole genome sequencing of ten patients | Oncotarget | David G. Darcy | Rachel Chiaroni-Clarke, Jennifer M. Murphy, Joshua N. Honeyman, Umesh Bhanot, Michael P. LaQuaglia | Sanford M. Simon | The genomic landscape of fibrolamellar hepatocellular carcinoma: whole genome sequencing of ten patients |
| 6-Oct-15 | Model of fibrolamellar hepatocellular carcinomas reveals striking enrichment in cancer stem cells | Nature Communications | Tsunekazu Oikawa, Eliane Wauthier | Timothy A. Dinh, Sara R. Selitsky, Andrea Reyna-Neyra, Guido Carpino, Ronald Levine, Vincenzo Cardinale, David Klimstra, Eugenio Gaudio, Domenico Alvaro, Nancy Carrasco | Praveen Sethupathy, Lola M. Reid | Model of fibrolamellar hepatocellular carcinomas reveals striking enrichment in cancer stem cells |
| 1-Sep-17 | Molecular testing for the clinical diagnosis of fibrolamellar carcinoma | Modern Pathology | Rondell P Graham | Matthew M Yeh, Dora Lam-Himlin, Lewis R Roberts, Luigi Terracciano, Michael W Cruise, Patricia T Greipp, Riyam T Zreik, Dhanpat Jain, Nida Zaid, Safia N Salaria, Long Jin, Xiaoke Wang, Jeanette G Rustin, Sarah E Kerr, William R Sukov, David A Solomon, Sanjay Kakar, Emily Waterhouse, Ryan M Gill, Linda Ferrell, Venancio AF Alves, Deniz Nart, Funda Yilmaz, Stephanie Roessler, Thomas Longerich, Peter Schirmacher | Michael S Torbenson | Molecular testing for the clinical diagnosis of fibrolamellar carcinoma |
| 1-Dec-17 | CRISPR/Cas9 Engineering of Adult Mouse Liver Demonstrates that the DNAJB1-PRKACA Gene Fusion Is Sufficient to Induce Tumors Resembling Fibrolamellar Hepatocellular Carcinoma | Gastroenterology | Lars H. Engelholm | Anjum Riaz, Denise Serra, Frederik Dagnæs-Hansen, Jens V. Johansen, Eric Santoni-Rugiu, Steen H. Hansen | Francesco Niola, Morten Frödin | CRISPR/Cas9 Engineering of Adult Mouse Liver Demonstrates that the DNAJB1-PRKACA Gene Fusion Is Sufficient to Induce Tumors Resembling Fibrolamellar Hepatocellular Carcinoma |
| 31-Jan-19 | Road map for fibrolamellar carcinoma: progress and goals of a diversified approach | Journal of Hepatocellular Carcinoma | Edward R Kastenhuber | John Craig, Jon Ramsey, Kevin M Sullivan, Julien Sage, Sofia de Oliveira, Kimberly J Riehle, John D Scott, John D Gordan, Nabeel Bardeesy | Ghassan K Abou-Alfa | Road map for fibrolamellar carcinoma: progress and goals of a diversified approach |
| 11-Feb-19 | MicroRNA-375 Suppresses the Growth and Invasion of Fibrolamellar Carcinoma | Cellular and Molecular Gastroenterology and Hepatology | Timothy A. Dinh, Mark L. Jewell, Matt Kanke | Adam Francisco, Ramja Sritharan, Rigney E. Turnham, Seona Lee, Edward R. Kastenhuber, Eliane Wauthier, Cynthia D. Guy, Raymond S. Yeung, Scott W. Lowe, Lola M. Reid, John D. Scott, Anna M. Diehl | Praveen Sethupathy | MicroRNA-375 Suppresses the Growth and Invasion of Fibrolamellar Carcinoma |
| 7-May-19 | Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma | eLife | Rigney E Turnham | F Donelson Smith, Heidi L Kenerson, Mitchell H Omar, Martin Golkowski, Irvin Garcia, Renay Bauer, Ho-Tak Lau, Kevin M Sullivan, Lorene K Langeberg, Shao-En Ong, Kimberly J Riehle, Raymond S Yeung | John D Scott | Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma |
| 5-Feb-20 | Predictors of Outcome in Patients With Fibrolamellar Carcinoma: Analysis of the National Cancer Database | Anticancer Research | Hussein A Assi | Sarbajit Mukherjee, Michael Machiorlatti, Sara Vesely, Vipul Pareek | Hassan Hatoum | Predictors of Outcome in Patients With Fibrolamellar Carcinoma: Analysis of the National Cancer Database |
| 12-Feb-20 | Using dual checkpoint blockade to treat fibrolamellar hepatocellular carcinoma | Gut | Enrico N De Toni | Daniel Roessler | Using dual checkpoint blockade to treat fibrolamellar hepatocellular carcinoma | |
| 18-Jul-21 | Fibrolamellar carcinoma: An entity all its own | Current Problems in Cancer | Allison F. O’Neill | Alanna J. Church, Antonio R. Perez-Atayde, Raja Shaikh, Karen J. Marcus | Khashayar Vakili | Fibrolamellar carcinoma: An entity all its own |
| 1-Oct-21 | Identification of Novel Therapeutic Targets for Fibrolamellar Carcinoma Using Patient Derived Xenografts and Direct from Patient Screening | Cancer Discovery | Gadi Lalazar | David Requena, Lavoisier Ramos-Espiritu, Denise Ng, Patrick D. Bhola, Ype P. de Jong, Ruisi Wang, Nicole J. C. Narayan, Bassem Shebl, Solomon Levin, Eleftherios Michalidis, Mohammad Kabbani, Koen O. A. Vercauteren, Arlene M. Hurley, Benjamin A. Farber, William J. Hammond, James A. Saltsman III, Ethan M. Weinberg, J. Fraser Glickman, Barbara A. Lyons, Jessica Ellison, Erik Schadde, Martin Hertl, Jennifer L. Leiting, Mark J. Truty, Rory L. Smoot, Faith Tierney, Tomoaki Kato, Hans-Guido Wendel, Michael P. La Quaglia, Charles M. Rice, Anthony Letai, Philip Coffino, Michael S. Torbenson, Michael V. Ortiz | Sanford M. Simon | Identification of Novel Therapeutic Targets for Fibrolamellar Carcinoma Using Patient Derived Xenografts and Direct from Patient Screening |
| 15-Feb-22 | DNAJB1-PRKACA in HEK293T cells induces LINC00473 overexpression that depends on PKA signaling | PLOS ONE | Stephanie S. Kim, Ina Kycia, Michael Karski, Rosanna K. Ma | Evan A. Bordt, Julian Kwan, Anju Karki, Elle Winter, Ranan G. Aktas, Yuxuan Wu, Andrew Emili, Daniel E. Bauer, Praveen Sethupathy | Khashayar Vakili | DNAJB1-PRKACA in HEK293T cells induces LINC00473 overexpression that depends on PKA signaling |
| 22-Feb-22 | A framework for fibrolamellar carcinoma research and clinical trials | Nature Reviews Gastroenterology & Hepatology | Timothy A. Dinh, Alan F. Utria, Kevin C. Barry | Rosanna Ma, Ghassan K. Abou- Alfa, John D. Gordan, Elizabeth M. Jaffee, John D. Scott, Jessica Zucman-Rossi, Allison F. O’Neill | Mark E. Furth, Praveen Sethupathy | A framework for fibrolamellar carcinoma research and clinical trials |
| 18-Apr-22 | Multi-omic analysis of microRNA-mediated regulation reveals a proliferative axis involving miR-10b in fibrolamellar carcinoma | JCI Insight | Adam B. Francisco | Matt Kanke, Andrew P. Massa, Timothy A. Dinh, Ramja Sritharan, Khashayar Vakili, Nabeel Bardeesy | Praveen Sethupathy | Multi-omic analysis of microRNA-mediated regulation reveals a proliferative axis involving miR-10b in fibrolamellar carcinoma |
| 13-May-22 | Histologic type predicts disparate outcomes in pediatric hepatocellular neoplasms: A Pediatric Surgical Oncology Research Collaborative study | Cancer | Scott S Short | Zachary J Kastenberg, Guo Wei, Alex Bondoc, Roshni Dasgupta, Greg M Tiao, Erin Watters, Todd E Heaton, Dimitra Lotakis, Michael P La Quaglia, Andrew J Murphy, Andrew M Davidoff, Sara A Mansfield, Max R Langham, Timothy B Lautz, Riccardo A Superina, Katherine C Ott, Marcus M Malek, Katrina M Morgan, Eugene Kim, Abigail Zamora, Danny Lascano, Jonathan Roach, Joseph T Murphy, David H Rothstein, Sanjeev A Vasudevan, Richard Whitlock, Dave R Lal, Brian Hallis, Andreana Bütter, Reto M Baertschiger, Eveline Lapidus-Krol, Juan Putra, Elisabeth R Tracy, Jennifer H Aldrink, Jordan Apfeld, Hau D Le, Keon Y Park, Barrie S Rich, Richard D Glick, Elizabeth A Fialkowski, Alan F Utria, Rebecka L Meyers | Kimberly J Riehle | Histologic type predicts disparate outcomes in pediatric hepatocellular neoplasms: A Pediatric Surgical Oncology Research Collaborative study |
| 8-Sep-22 | β-catenin cancer–enhancing genomic regions axis is involved in the development of fibrolamellar hepatocellular carcinoma | Hepatology Communications | Ruhi Gulati | Michael Johnston, Maria Rivas, Ashley Cast, Meenasri Kumbaji, Margaret A. Hanlon, Sanghoon Lee, Ping Zhou, Charissa Lake, Emily Schepers, Kyung-Won Min, Je-Hyun Yoon, Rebekah Karns, Lola M. Reid, Dolores Lopez-Terrada, Lubov Timchenko, Sreeja Parameswaran, Matthew T. Weirauch, Sarangarajan Ranganathan, Alexander Bondoc, James Geller, Gregory Tiao, Soona Shin | Nikolai Timchenko | β-catenin cancer–enhancing genomic regions axis is involved in the development of fibrolamellar hepatocellular carcinoma |
| 8-Sep-22 | Targeting BCL-XL in fibrolamellar hepatocellular carcinoma | JCI Insight | Bassem Shebl, Denise Ng, Gadi Lalazar | Carly Rosemore, Tova M. Finkelstein, Rachael D. Migler, Guangrong Zheng, Peiyi Zhang, Caroline S. Jiang, Adam Qureshi, Roger Vaughan, Mark Yarchoan, Ype P. de Jong, Charles M. Rice, Philip Coffino, Michael V. Ortiz, Daohong Zhou | Sanford M. Simon | Targeting BCL-XL in fibrolamellar hepatocellular carcinoma |
| 17-Oct-22 | Clinical and demographic predictors of survival for fibrolamellar carcinoma patients—A patient community, registry‐based study | Hepatology Communications | Amichai Berkovitz | Rachael D. Migler, Adam Qureshi,Carly Rosemore, Michael S. Torbenson,Roger Vaughan, Erin Marcotte | Sanford M. Simon | Clinical and demographic predictors of survival for fibrolamellar carcinoma patients—A patient community, registry‐based study |
| 27-Oct-22 | The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma | Nature Communications | Jens Bauer | Natalie Köhler, Yacine Maringer, Philip Bucher, Tatjana Bilich, Melissa Zwick, Severin Dicks, Annika Nelde, Marissa Dubbelaar, Jonas Scheid, Marcel Wacker, Jonas S. Heitmann, Sarah Schroeder, Jonas Rieth, Monika Denk, Marion Richter, Reinhild Klein, Irina Bonzheim, Julia Luibrand, Ursula Holzer, Martin Ebinger, Ines B. Brecht, Michael Bitzer, Melanie Boerries, Judith Feucht, Helmut R. Salih, Hans-Georg Rammensee, Stephan Hailfinger | Juliane S. Walz | The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma |
| 30-Oct-22 | Clinical Outcomes in Fibrolamellar Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors | Cancers | Krista Y Chen, Aleksandra Popovic | David Hsiehchen, Marina Baretti, Paige Griffith, Ranjan Bista, Azarakhsh Baghdad4, Ihab R Kamel, Sanford M Simon, Rachael D Migler | Mark Yarchoan | Clinical Outcomes in Fibrolamellar Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors |
| 9-Dec-22 | Fibrolamellar carcinoma transcriptomic-based treatment prediction: complete response after nivolumab and ipilimumab | Journal for ImmunoTherapy of Cancer | Raanan Berger | Gal Dinstag, Omer Tirosh, Eyal Schiff, David Kleiner, Kenneth D Aldape, Eytan Ruppin, Tuvik Beker | Razelle Kurzrock | Fibrolamellar carcinoma transcriptomic-based treatment prediction: complete response after nivolumab and ipilimumab |
| 4-Jan-23 | Oncogenic Addiction of Fibrolamellar Hepatocellular Carcinoma to the Fusion Kinase DNAJB1-PRKACA | Clinical Cancer Research | Christoph Neumayer | Denise Ng, Caroline S. Jiang, Adam Qureshi, Gadi Lalazar, Roger Vaughan | Sanford M. Simon | Oncogenic Addiction of Fibrolamellar Hepatocellular Carcinoma to the Fusion Kinase DNAJB1-PRKACA |
| 23-Mar-23 | Defining incidence and complications of fibrolamellar liver cancer through tiered computational analysis of clinical data | npj Precision Oncology | Travis Zack, Kurt P. Losert | Samantha M. Maisel, Jennifer Wild, Amin Yaqubie, Michael Herman, Jennifer J. Knox, Robert J. Mayer, Alan P. Venook, Atul Butte, Allison F. O’Neill, Ghassan K. Abou-Alfa | John D. Gordan | Defining incidence and complications of fibrolamellar liver cancer through tiered computational analysis of clinical data |
| 3-May-23 | Organoid models of fibrolamellar carcinoma mutations reveal hepatocyte transdifferentiation through cooperative BAP1 and PRKAR2A loss | Nature Communications | Laura Rüland | Francesco Andreatta, Simone Massalini, Susana Chuva de Sousa Lopes, Hans Clevers | Delilah Hendriks, Benedetta Artegiani | Organoid models of fibrolamellar carcinoma mutations reveal hepatocyte transdifferentiation through cooperative BAP1 and PRKAR2A loss |
| 21-Jun-23 | program approach to rare tumors: Natural history study of rare solid tumors in children and adults: A longitudinal, comprehensive data and biospecimen collection protocol | Pediatric Blood & Cancer | Mary Frances Wedekind | Karlyne M. Reilly, Jaydira Del Rivero, Robin Lockridge, Taryn Allen, Margarita Raygada, Donna Bernstein, Barbara J. Thomas, Christina Vivelo, Jason Levine, Nurlan Shonkoev, Kenneth Aldape, John Glod, Abby B. Sandler, Brigitte C. Widemann | Mary Frances Wedekind | NCI intramural program approach to rare tumors: Natural history study of rare solid tumors in children and adults: A longitudinal, comprehensive data and biospecimen collection protocol |
| 21-Jun-23 | Disruption of proteome by an oncogenic fusion kinase alters metabolism in fibrolamellar hepatocellular carcinoma | Science Advances | Solomon N. Levin | Michael D. Tomasini, James Knox, Mahsa Shirani, Bassem Shebl, David Requena, Jackson Clark, Søren Heissel, Hanan Alwaseem | Sanford M. Simon | Disruption of proteome by an oncogenic fusion kinase alters metabolism in fibrolamellar hepatocellular carcinoma |
| 1-Mar-24 | Reversing immunosuppression in the tumor microenvironment of fibrolamellar carcinoma via PD‑1 and IL‑10 blockade | Nature Scientific Reports | S. K. Daniel, K. M. Sullivan | L. K. Dickerson, R. J. E. van den Bijgaart, A. F. Utria, K. P. Labadie, H. L. Kenerson, X. Jiang, K. S. Smythe, J. S. Campbell, R. H. Pierce, T. S. Kim, K. J. Riehle, R. S. Yeung, J. A. Carter, K. C. Barry | V. G. Pillarisetty | Reversing immunosuppression in the tumor microenvironment of fibrolamellar carcinoma via PD‑1 and IL‑10 blockade |
| 19-Mar-24 | DNAJB1-PRKACA fusion neoantigens elicit rare endogenous T cell responses that potentiate cell therapy for fibrolamellar carcinoma | Cell Reports Medicine | Allison M. Kirk | Jeremy Chase Crawford, Ching-Heng Chou, Cliff Guy, Kirti Pandey, Tanya Kozlik, Ravi K. Shah, Shanzou Chung, Phuong Nguyen, Xiaoyu Zhang, Jin Wang, Matthew Bell, Robert C. Mettelman, E. Kaitlynn Allen, Mikhail V. Pogorelyy, Hyunjin Kim, Anastasia A. Minervina, Walid Awad, Resha Bajracharya, Toni White, Donald Long, Jr., Brittney Gordon, Michelle Morrison, Evan S. Glazer, Andrew J. Murphy, Yixing Jiang, Elizabeth A. Fitzpatrick, Mark Yarchoan, Praveen Sethupathy, Nathan P. Croft, Anthony W. Purcell,∙ Sara M. Federico, Elizabeth Stewart, Stephen Gottschalk, Anthony E. Zamora, Christopher DeRenzo, Scott E. Strome | Paul G. Thomas | DNAJB1-PRKACA fusion neoantigens elicit rare endogenous T cell responses that potentiate cell therapy for fibrolamellar carcinoma |
| 21-Mar-24 | DNAJB1-PRKACA fusion protein-regulated LINC00473 promotes tumor growth and alters mitochondrial fitness in fibrolamellar carcinoma | Plos Genetics | Rosanna K. Ma | Pei-Yin Tsai, Alaa R. Farghli, Alexandria Shumway, Matt Kanke, John D. Gordan, Taranjit S. Gujral, Khashayar Vakili, Manabu Nukaya, Leila Noetzli, Sean Ronnekleiv-Kelly, Wendy Broom, Joeva Barrow | Praveen Sethupathy | DNAJB1-PRKACA fusion protein-regulated LINC00473 promotes tumor growth and alters mitochondrial fitness in fibrolamellar carcinoma |
| 28-Aug-24 | Proteo-metabolomics and patient tumor slice experiments point to amino acid centrality for rewired mitochondria in fibrolamellar carcinoma | Cell Reports Medicine | Donald Long Jr | Marina Chan, Mingqi Han, Zeal Kamdar, Rosanna K Ma, Pei-Yin Tsai, Adam B Francisco, Joeva Barrow, David B Shackelford, Mark Yarchoan, Matthew J McBride, Lukas M Orre, Nathaniel M Vacanti, Taranjit S Gujral | Praveen Sethupathy | Proteo-metabolomics and patient tumor slice experiments point to amino acid centrality for rewired mitochondria in fibrolamellar carcinoma |
| 27-Sep-24 | DNAJB1-PRKACA fusion drives fibrolamellar liver cancer through impaired SIK signaling and CRTC2/p300-mediated transcriptional reprogramming | Cancer Discovery | Ilaria Gritti | Jinkai Wan, Vajira Weeresekara, Joel M. Vaz, Giuseppe Tarantino, Tenna Holgersen Bryde, Vindhya Vijay, Ashwin V. Kammula, Prabhat Kattel, Songli Zhu, Phuong Vu, Marina Chan, Meng-Ju Wu, John D. Gordan, Krushna C. Patra, Vanessa S. Silveira, Robert T. Manguso, Marc N. Wein, Christopher J. Ott, Jun Qi, David Liu, Kei Sakamoto | Taranjit S. Gujral, Nabeel Bardeesy | DNAJB1-PRKACA fusion drives fibrolamellar liver cancer through impaired SIK signaling and CRTC2/p300-mediated transcriptional reprogramming |
| 7-Oct-24 | Rare primary liver cancers: An EASL position paper | Journal of Hepatology | Henning Wege | Claudia Campani, Ruben de Kleine, Tim Meye, Jean-Charles Nault, Timothy M. Pawlik, Maria Reig, Jens Ricke, Christine Sempoux, Guido Torzilli, Jessica Zucman-Rossi | Henning Wege | Rare primary liver cancers: An EASL position paper |
| 30-Dec-24 | Liver cancer multiomics reveals diverse protein kinase A disruptions convergently produce fibrolamellar hepatocellular carcinoma | Nature Communications | David Requena | Jack A. Medico, Luis F. Soto-Ugaldi, Mahsa Shirani, James A. Saltsman III, Michael S. Torbenson, Philip Coffino | Sanford M. Simon | Liver cancer multiomics reveals diverse protein kinase A disruptions convergently produce fibrolamellar hepatocellular carcinoma |
| 25-Apr-25 | Specific degrader for fusion oncokinase kills tumors and is augmented by bimodal degrader-siRNA | bioRxiv | Mahsa Shirani | Ronaldo Shaquille Bowie, Michael Tomasini, Ruth Hook, Denise Ng, Bassem Shebl, Barbara Lyons, Philip Coffino | Sanford M. Simon | Specific degrader for fusion oncokinase kills tumors and is augmented by bimodal degrader-siRNA |
| 6-Nov-25 | DNAJ-PKAc induces metabolic wiring and enhanced glutamine flux in fibrolamellar HCC | Journal of Hepatology | Zeal Kamdar | Ethan Neumann, Kathryn Howe, Donald Long Jr., Waqar Arif, Daniel H. Shu, Aditya Mohan, Emma Kartalia, Jeric Hernandez, Solomon Levin, Kylie Belanger, Kayla Bendinelli Tamara Y. Lopez-Vidal , James M. Leatherman, Kabeer Munjal, Cissy Zhang, Pratik Khare, Paul G. Thomas, Daniel J. Zabransky, Won Jin Ho, Robert D. Leone, Robert A. Anders, Anne Le, Praveen Sethupathy, Chi V. Dang, Elizabeth M. Jaffee | Mark Yarchoan | DNAJ-PKAc induces metabolic wiring and enhanced glutamine flux in fibrolamellar HCC |
| 20-Nov-25 | Serum Procalcitonin: A Novel Tumor Biomarker for Diagnosis and Follow-Up in Fibrolamellar Hepatocellular Carcinoma | bioRxiv | Jean-Charles Naul | Claudia Campani, Theo Z Hirsch, Ethan Neumann, Waqar Arif, Sandrine Imbeaud, Marina Baretti, Marianne Ziol, Sabrina Sidali, Pauline Roger, Manon Allaire, Mohamed Bouattour, Fabio Marra, Brice Fresneau, Neus Llarch, Jean-Marie Peron, René Gerolami, Eric Nguyen Khac, Pierre Nahon, Nathalie Ganne-Carrié, Julien Caldéraro, Aurélie Beaufrère, Valérie Paradis, Catherine Guettier, Angela Sutton | Mark Yarchoan, Jessica Zucman-Rossi | Serum Procalcitonin: A Novel Tumor Biomarker for Diagnosis and Follow-Up in Fibrolamellar Hepatocellular Carcinoma |
| 24-Nov-25 | A Therapeutic Peptide Vaccine for Fibrolamellar Hepatocellular Carcinoma: A Phase 1 Trial | Nature Medicine | Marina Baretti | Allison M. Kirk, Brian H. Ladle, Zeal Kamdar, Kayla J. Bendinelli, Won Jin Ho, Samir Adhikari, Nicholas A. Clark, Balaji Sundararaman, Hao Wang, Heng-Chung Kung, Jeric Hernandez, Hanfei Qi, Sarah M. Shin, Alexei Hernandez, Mari Nakazawa, Stefan A. Schattgen, Jeremy Chase Crawford, Mark Furth, Robert A. Anders, Chris Thoburn, Neeha Zaidi, Amanda L. Huff, Julie Nauroth | Mark Yarchoan | A Therapeutic Peptide Vaccine for Fibrolamellar Hepatocellular Carcinoma: A Phase 1 Trial |
| 19-Dec-25 | CDK7 is a novel therapeutic target in fibrolamellar carcinoma | iScience | Manabu Nukaya | Patrick R. Carney, Crystal Cafferty, Katerina Zahed, Isabelle Yun, David P. Al-Adra, Noor A. Kazim, Alaa R. Farghli, Marina Chan, Austin Stram, Jeremy D. Kratz, Mark E. Berres, Andrew Yen, Taranjit S. Gujral, Praveen Sethupathy, Christopher A. Bradfield | Sean M. Ronnekleiv-Kelly | CDK7 is a novel therapeutic target in fibrolamellar carcinoma |
| 18-Mar-26 | Clinical Guideline for the Diagnosis and Treatment of Fibrolamellar Carcinoma (FLC) | Hepatology Communications | Allison F. O’Neill, Emily L. Zeme | Ghassan K. Abou-Alfa, Marina Baretti, Alexander J. Bondoc, Alanna Church, Cristina R. Ferrone, Megan Fitzgerald, James I. Geller, Anne E. Gill, William P. Harris, Heung Bae Kim, Sunyoung S. Lee, Kevin X. Liu, Michael V. Ortiz, Arun Rangaswami, Kimberly J. Riehle, Abby R. Rosenberg, Michael S. Torbenson, Mark Yarchoan | Allison F. O’Neill, John D. Gordan | Clinical Guideline for the Diagnosis and Treatment of Fibrolamellar Carcinoma (FLC) |